StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Gain Therapeutics's enterprise value was $35.37M on Nov 11, 2026, against $117.50M a year earlier. Over the last 5 years it ranged from $1.69M to $117.50M, with a median of $36.70M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$35.37M-67.1%
2025Dec 31, 2025$107.42M+141.5%
2024Dec 31, 2024$44.49M+48.4%
2023Dec 29, 2023$29.98M+99.6%
2022Dec 30, 2022$15.02M-37.9%
2021Dec 31, 2021$24.20M–

More Gain Therapeutics figures

See a number that looks wrong?